Related Experiment Video
Updated: Apr 9, 2026
06:59
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
11.5K
Assessing Prothrombin Time and Activated Partial Thromboplastin Time Variations with Glycemic Status: A
Mansha Dua1, S D Baby Sruthi, S R Ranga Bashyam
1Department of General Medicine, Vinayaka Mission's Kirupananda Variyar Medical College and Hospitals, Vinayaka Mission's Research Foundation (DU), Salem, Tamil Nadu, India.
Annals of African Medicine
|April 8, 2026
Summary
Poor glycemic control in diabetes is linked to altered blood clotting. Diabetic patients showed shorter activated partial thromboplastin time (aPTT) and prolonged prothrombin time (PT)/international normalized ratio (INR), indicating a higher risk of thrombosis.
Area of Science:
- Hematology
- Endocrinology
- Clinical Biochemistry
Background:
- Diabetes mellitus is characterized by chronic hyperglycemia, leading to nonenzymatic glycation of coagulation proteins and a pro-thrombotic state.
- While prothrombin time (PT) and activated partial thromboplastin time (aPTT) assess coagulation, their relationship with glycemic control in India requires further documentation.
- Assessing PT, international normalized ratio (INR), and aPTT alongside glycated hemoglobin (HbA1c) can elucidate coagulation changes in diabetic individuals.
Purpose of the Study:
- To compare PT, INR, and aPTT values between diabetic and nondiabetic individuals.
- To evaluate the association between these coagulation parameters and glycemic status (HbA1c).
Main Methods:
- A cross-sectional study included 100 participants aged 18-60, categorized into diabetic and nondiabetic groups.
- Exclusion criteria included anticoagulant use, coagulation disorders, sepsis, malignancy, and type 1 diabetes.
- Coagulation parameters were analyzed using turbidometric methods.
Main Results:
- Diabetic patients exhibited significantly shortened aPTT and mildly prolonged PT/INR compared to nondiabetics, suggesting a pro-thrombotic tendency.
- HbA1c demonstrated a negative correlation with aPTT and a positive correlation with PT/INR.
- These coagulation alterations were more pronounced in individuals with HbA1c >8%.
Conclusions:
- Poor glycemic control in diabetes is associated with significant changes in coagulation, including shortened aPTT and prolonged PT/INR.
- These findings support a pro-thrombotic environment in diabetic individuals.
- Routine coagulation screening in poorly controlled diabetics may identify individuals at increased risk for thrombotic events.
Keywords:
Activated partial thromboplastin timeTemps de céphaline activéecoagulation profilediabetes mellitusdiabète sucréglycated hemoglobinhypercoagulabilityhypercoagulabilitéhémoglobine glyquéeinternational normalized ratioprofil de coagulationprothrombin timeratio international normalisétemps de prothrombineMore Related Videos
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
5.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.6K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
261
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
261
01:23Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
119
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
119
01:16Hormones Regulating Blood Glucose
8.7K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
8.7K